Answers are grounded in this paper and cite their sources.
Background Fanconi anemia (FA) is a rare pediatric disease that is characterized by bone marrow failure, congenital abnormalities, and a heightened risk of cancer. Currently, the only curative treatment for FA is hematopoietic stem cell transplantation (HSCT). Historically, patients with FA have experienced elevated rates of graft-versus-host disease (GVHD) and other transplant-related complications following HSCT. Purpose To synthesize current knowledge on HSCT in patients with FA and to examine current recommendations to improve patient outcomes and reduce morbidity and mortality. Methods A search was conducted in Scopus and PubMed for articles about FA and HSCT. Articles were screened by title and abstract to identify relevant ones that fit the inclusion and exclusion criteria. A total of 18 publications were included in this systematic review. Results Outcomes for HSCT in FA patients have improved over recent years due to changes in conditioning regimens, donor selection, and stem cell source selection. Optimizing conditioning regimens may improve outcomes and reduce the risks of GVHD, graft failure, and treatment-related infections. New Post-HSCT late effects are identified due to improved overall survival. Conclusion New techniques and methods in HSCT have led to better overall survival for FA patients worldwide. Some of these methods are more difficult to implement in low-income areas. Continued research and development are needed to allow improved access in those areas. Long-term post-transplant monitoring needs to be more rigorous for early identification of possible late effects.
No takes yet. Share an insight, caveat, or question.
Oliver et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: